Skip to main content
UniHealth

Doctor search

Rayhan Adi Lal, MD

Endocrinology · Stanford

NPI 1083846166

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
13
2 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

13 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lal’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

13 of 13 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A123327 · Current

Licensed to practise in California · since 2012 · expires 2026-10-31 · University of California, Davis School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$5,822

Medicare paid this office $5,822 for 20 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)12$3,818$153

Who their Medicare patients are

20 Original Medicare patients in 2024. Average age 62 · Health risk score 2.40. Sicker patients than 9 in 10 peers; the typical endocrinology clinician is at 1.46.

Conditions among them: High blood pressure 70% · Diabetes 65%.

The office billed $32,468, Medicare allowed $7,931 and paid $5,822; for 48 services of 5 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20242048622.40$32,468$5,822
20232148621.76$27,243$4,657
20222151671.55$26,295$4,017
20201540671.87$11,804$3,228

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

Drugs they prescribed that Part D paid

$71,535

Pharmacies billed $71,535 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 74) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.

0 generic and 43 brand-name prescriptions · $71,535 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Levothyroxine12$102$8

Year by year

Part D prescribing by year
202474110% (0)58%$71,535
202374None0% (0)68%$100,491
202271None0% (0)75%$54,924
202143None0% (0)63%$16,986
201635None0% (0)None$1,526
201527819None17%$11,717
2014265274% (11)None$36,422
201368120% (0)None$21,678

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 3 drugs

Part D drugs prescribed in 2023
Afrezza11$34,812$3,165
Jardiance12$8,686$724
Levothyroxine11$168$15

2022: 1 drug

Part D drugs prescribed in 2022
Jardiance21$12,247$583

2021: 2 drugs

Part D drugs prescribed in 2021
Jardiance14$7,619$544
Levothyroxine13$335$26

2015: 8 drugs

Part D drugs prescribed in 2015
Atorvastatin26$292$11
Finasteride18$189$11
Omeprazole22$157$7
Benazepril29$128$4
Metformin24$120$5
Losartan19$87$5
Amlodipine Besylate17$86$5
Atenolol16$85$5

2014: 9 drugs

Part D drugs prescribed in 2014
Atorvastatin23$412$18
Omeprazole20$167$8
Metformin18$155$9
Finasteride13$112$9
Amlodipine Besylate14$84$6
Losartan12$82$7
Tramadol11$76$7
Simvastatin12$75$6
Benazepril12$71$6

Money from drug and device companies

$613 in 2025

Industry payments by year
202546None$613
202433$895$1,227
202326$10,200$10,939
202223None$923
202122$2,875$2,921
202024$4,263$4,342
201957$6,200$6,586

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Sequel Med TechTwiist$233
3 payments
  • Meals for Twiist · 2025-12-03 · $10
  • Meals for Twiist · 2025-09-29 · $62
  • Meals for Twiist · 2025-01-22 · $161
Sanofi-Aventis U.S.Tzield$170
1 payment
  • Meals for Tzield · 2025-07-13 · $170
DexcomDexcom G6 Transmitter$153
1 payment
  • Meals for Dexcom G6 Transmitter · 2025-10-23 · $153
Tandem Diabetes CareT:Slim X2 Insulin Pump With Control-Iq$57
1 payment
  • Meals for T:Slim X2 Insulin Pump With Control-Iq · 2025-06-22 · $57
See all 6 published payments
Every published payment
Sequel Med TechMeals · 2025-12-03Twiist$10
DexcomMeals · 2025-10-23Dexcom G6 Transmitter$153
Sequel Med TechMeals · 2025-09-29Twiist$62
Sanofi-Aventis U.S.Meals · 2025-07-13Tzield$170
Tandem Diabetes CareMeals · 2025-06-22T:Slim X2 Insulin Pump With Control-Iq$57
Sequel Med TechMeals · 2025-01-22Twiist$161
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $1,227

Payments by company in 2024
Sanofi-Aventis U.S.None$895
1 payment
  • Consulting · 2024-06-14 · $895
Tandem Diabetes CareT:Slim X2 Insulin Pump With Control-Iq$211
1 payment
  • Meals for T:Slim X2 Insulin Pump With Control-Iq · 2024-03-29 · $211
Abbott LaboratoriesFreestyle Libre 3$121
1 payment
  • Meals for Freestyle Libre 3 · 2024-01-29 · $121

2023: $10,939

Payments by company in 2023
Eli Lilly andNone$5,689
4 payments
  • Meals · 2023-07-06 · $50
  • Travel · 2023-07-06 · $160
  • Consulting · 2023-06-15 · $4,950
  • Travel · 2023-06-09 · $529
Abbott LaboratoriesFreestyle Libre Pro$5,250
2 payments
  • Consulting for Freestyle Libre Pro · 2023-06-28 · $3,750
  • Consulting for Freestyle Libre Pro · 2023-05-03 · $1,500

2022: $923

Payments by company in 2022
Intuitive SurgicalDa Vinci Surgical System$800
2 payments
  • Education for Da Vinci Surgical System · 2022-06-22 · $500
  • Education for Da Vinci Surgical System · 2022-06-22 · $300
SenseonicsEversense$123
1 payment
  • Meals for Eversense · 2022-07-30 · $123

2021: $2,921

Payments by company in 2021
Abbott LaboratoriesFreestyle Libre$2,875
1 payment
  • Consulting for Freestyle Libre · 2021-04-26 · $2,875
MedtronicNone$46
1 payment
  • Meals · 2021-12-09 · $46

2020: $4,342

Payments by company in 2020
Abbott LaboratoriesFreestyle Libre$4,263
2 payments
  • Consulting for Freestyle Libre · 2020-08-31 · $2,413
  • Consulting for Freestyle Libre · 2020-03-24 · $1,850
Medtronic MiniMedNone$80
2 payments
  • Meals · 2020-10-15 · $53
  • Meals · 2020-01-15 · $26

2019: $6,586

Payments by company in 2019
Abbott LaboratoriesFreestyle Libre$6,200
2 payments
  • Consulting for Freestyle Libre · 2019-09-24 · $4,050
  • Consulting for Freestyle Libre · 2019-03-20 · $2,150
Tandem Diabetes CareT-Slim Insulin Pump$140
2 payments
  • Meals for T-Slim Insulin Pump · 2019-06-14 · $1
  • Meals for T-Slim Insulin Pump · 2019-06-05 · $139
Novo NordiskOzempic$123
1 payment
  • Meals for Ozempic · 2019-12-03 · $123
DexcomDexcom Cgm$109
1 payment
  • Meals for Dexcom Cgm · 2019-02-21 · $109
MannkindAfrezza$14
1 payment
  • Meals for Afrezza · 2019-05-08 · $14

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Medtronic, Inc. · Cip337 Succeed · 2023Their institution$276,196
Medtronic, Inc. · Cip344 Succeed2 · 2025Their institution$199,100
Medtronic, Inc. · Cip335 Lyumjev · 2023Their institution$84,725
Medtronic, Inc. · Cip335 Lyumjev · 2022Their institution$64,040
Insulet Corporation · Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery Systemin Adults With Type 2 Diabetes · 2023Their institution$41,300
Medtronic, Inc. · Cip337 Succeed · 2024Their institution$16,336
Medtronic, Inc. · Cip335 Lyumjev · 2024Their institution$9,093
Insulet Corporation · Safety and Efficacy of the Omnipodtm 5 Automated Insulin Delivery Systemin Adults With Type 2 Diabetes · 2023Their institution$1,600
Insulet Corporation · Efficacy and Safety of the Omnipod 5 System Compared To Pump Therapy in the Treatment of Type 1 Diabetes: · 2024Their institution$1,329

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1083846166
Licence
CA A123327California A123327: Current · expires 2026-10-31
Trained
University of California, Davis School of Medicine, 2011
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RE0101X (207RE0101X); Internal medicine (207R00000X); Pediatrics (208000000X); Federal specialty code 2080P0205X (2080P0205X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2009-08-21
NPI last updated
2024-04-25
NPI record certified
2024-04-25

This is when the NPI record was last certified, not a medical board exam.